The USAID Global Health Supply Chain Program (GHSC) is a collection of 8 complementary projects working globally to achieve stronger, more resilient health supply chains.
By incorporating lessons learned over the last decade of global health supply chain management, GHSC consolidates USAID’s primary supply purchasing and distribution power across the health sector, with increased efficiencies and cost savings to create one streamlined and integrated supply chain.
Program focus areas like procurement, last mile delivery, in-country technical assistance, capacity building, quality assurance, and service delivery, among others, work to ensure an uninterrupted stream of quality health products and services for millions of people.
In September 2018, Botswana became one of the first countries to transition to the combined drug regimen tenofovir, lamivudine and dolutegravir (TLD), a single-pill antiretroviral (ARV). TLD is the preferred first-line ARV for treating HIV because it is highly effective, safe, and proven to rapidly suppress viral load in adult and adolescent patients with HIV.
In September 2018, Botswana became one of the first countries to transition to the combined drug regimen tenofovir, lamivudine and dolutegravir (TLD), a single-pill antiretroviral (ARV). TLD is the preferred first-line ARV for treating HIV because it is highly effective, safe, and proven to rapidly suppress viral load in adult and adolescent patients with HIV.
